Research programme: skin disorder therapeutics- BioPharmX CorporationAlternative Names: BPX 02
Latest Information Update: 08 Mar 2016
At a glance
- Originator BioPharmX Corporation
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 08 Mar 2016 Early research in Skin disorders in USA (Topical)